Lipid-Lowering Agents - Benelux

Benelux

The Lipid-Lowering Agents market in the Benelux region is predicted to witness a significant surge in revenue, with projections indicating that it will reach a staggering US$92.07m by the year 2024.
Furthermore, this market is expected to exhibit a steady annual growth rate of -0.25% from 2024 to 2029, ultimately leading to a market volume of approximately US$90.93m by 2029.
In terms of global comparison, it is noteworthy to mention that United States is anticipated to generate the highest revenue in this market, with an estimated amount of US$4,461.00m in 2024.
The adoption of lipid-lowering agents in Benelux has increased significantly due to the high prevalence of cardiovascular diseases in the region.

Key regions: Europe, Brazil, France, Australia, Germany

Market

Region

Region comparison

Currency

Analyst Opinion

The demand for Lipid-Lowering Agents in Benelux has been on a steady rise in recent years.

Customer preferences: The increasing awareness of cardiovascular diseases and the need to maintain healthy cholesterol levels has been the primary driver of the Lipid-Lowering Agents market in Benelux. Additionally, the aging population and the rise in obesity rates have also contributed to the growth of the market.

Trends in the market: There has been a shift towards the use of combination therapies in the Lipid-Lowering Agents market in Benelux, with more patients opting for drugs that combine different mechanisms of action. This trend is driven by the need to achieve better lipid control and reduce the risk of cardiovascular events.

Local special circumstances: The healthcare systems in Benelux countries are well developed, and there is a high level of access to healthcare services. This has contributed to the growth of the Lipid-Lowering Agents market, as patients have easy access to these drugs. Additionally, there is a strong focus on preventive healthcare in the region, which has also driven demand for Lipid-Lowering Agents.

Underlying macroeconomic factors: The GDP per capita in Benelux countries is relatively high, which has contributed to the growth of the Lipid-Lowering Agents market. Additionally, the region has a high prevalence of cardiovascular diseases, which has created a significant market for Lipid-Lowering Agents. The region's strong pharmaceutical industry and research capabilities have also contributed to the growth of the market.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.